Kurt Gustafson: No, I mean, I think that’s right. When somebody says they’re going to do a reprioritization, is that truly reprioritization or is that a funding issue? I’m not sure we’ll know. But in some ways, I’m not sure it really matters to us. It’s a program that maybe is being delayed or not going to get the economics for us. So in some ways, it doesn’t necessarily matter.
Joe Pantginis: No, absolutely fair. And then the other topic is — and thank you for indulging me, obviously, I’m very happy to see the launch of DAB today. I’ll keep all the pictures of people dabbing out of my notes. So two parts there. So the first part is seeing the multi-block or building block potential of this makes me think of other companies, say like in the Anticalin space or what have you, where you could come up with a lot of unique structures. Do you have any early information about the ease or difficulties of future manufacturing of these sort of multifaceted structures? Are you looking to present any experimental data from the DAB program publicly? And then lastly, can you talk a little more with regard to DABs and their differentiation or more specific epitopes specificity compared to a traditional antibody. Does it change the calculus on clinical applications?
Matthew Foehr: Yes. Great question, Joe. I’ll let Bill comment on those. I will say that the early feedback from partners has been fantastic. Todd highlighted some of that in his section. But in terms of them understanding the part of the industry, the need that this technology can fill that initial feedback has been great. As I mentioned, we already have a couple of partners who have programs that are in progress that are already in progress. So those started here in the fourth quarter. But those are already moving in part. But Bill can talk about our disclosure plans. We have a couple of big presentations coming up from scientific conferences and then can address your other questions. So Bill.
Bill Harriman: Yes. We have a few presentations where we’re going to go into more depth about the qualities of the antibodies coming out from OmnidAb. So that will be next week in PEGS and also in AET in San Diego in December. And we’ll be continuing to talk about this as more data comes out. We have plans to publish a couple of papers on the topic and to answer your question a bit more specifically on developability, that’s something that we’ve looked at pretty hard because obviously, if you invest as much as we have in engineering Transgene, you want to make sure that you’ve got a good one. We’ve got a lot of good data and it’s growing, which will, I think, really, I would say, specify how developable these single-domain antibodies that come out of our platform are.
Now when it comes to linking multiple single-domain antibodies together, is it multispecific, hooking them to different types of moieties and some of that slide that I presented with all the different variations, obviously, we haven’t checked all of those. That’s too much to do just for us. I mean we will be working with our partners on that aspect. But I think at the core of it, if you can have very high-quality human single-domain units, you’re in a pretty good position to develop all of these kinds of molecules.
Joe Pantginis: Thank you, gentlemen.
Matthew Foehr: Thanks Joe.
Kurt Gustafson: All right. So it looks like the next question is coming in from Puneet. Go ahead, Puneet and looks like you’ve unmuted your line. Go ahead and ask your question.
Puneet Souda: Yeah, thanks guys. Thanks for hosting this. Hopefully, you can hear me well.
Kurt Gustafson: Yes.
Puneet Souda: Okay. Great. So first one, maybe a high level on the partner side, and then I want to get into technology question with Bill and Bob and the team on that. So maybe just how do you expect the partner mix to sort of change given the funding situation that is sort of finally caught up with antibody discovery part of the sector, too? I mean you might recall I was asking pretty much every quarter about that. But finally, we’re here. So now going forward, do you expect more collaboration, I mean more partnerships with larger pharma? And maybe just talk to us about that, how do you see the evolution in 2024? And I hear Kurt’s comments on the revenue side, but I just want to make sure I’m conceptualizing it correctly.
Matthew Foehr: Yes. Puneet. Thanks for the question and I’ll comment on the partnering landscape and Todd can fill in as well. What’s interesting the last two quarters, we’ve disclosed new partnerships with global big pharma companies. And that I think, is really a testament to the innovation work that this team and the team back in our labs are doing and also the visibility of the platform, the level of validation around the platform it’s definitely attracting the big pharma players who understand not only the technologies we have now and the level of validation work we put into them, but also our intellectual and business and scientific medical commitment to continued innovation. I think that’s what’s attracting some of those bigger partners.
But we are still signing up smaller partners as well. We announced a deal with GigaMune and Polaris Therapeutics this last quarter. So we are still seeing some of that, which is good. That’s counterbalanced by some of the examples I gave earlier of Seeker. And I’ll say our business development team has been as busy as ever. We have substantially expanded the team. Todd’s done a great job of bringing in a top-notch, I’ll say, science — scientifically trained and a BD team that really leans into the science because that’s something that our partners find of value. But Todd, maybe you can offer more color around migration and other things that have affected.
Todd Pettingill: Yes. That sounds good. Yes, it’s definitely — there’s been a lot of growth and as things have evolved, it might be helpful to talk to the sourcing of where these partner leads come in. Like Matt said, we’ve expanded the business development team significantly, and we spent a lot of time at conferences. Upcoming, there are some large ones antibodies, AET in San Diego. That’s a great source of leads. Also, we have our marketing team that really is going out in major publications. We’ve set up a series of webinars that drive interest. And then as Matt already mentioned, one of our biggest sources of new deals is what we call scientific migration. People that start in one company, they get familiar with the technology there, and then they move on to another company and they say, hey, I want to keep working with OmniAb. That drives a lot of our current deals.
